PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Jeito Capital co-leads €75m Series B financing in SparingVision

Jeito Capital (Jeito), an independent Private Equity firm dedicated to biotech and biopharma, has co-led a Series B financing round in SparingVision, a privately held French biotech company. 

As a spin-off of the Paris Vision Institute and the result of more than 20 years of scientific research, SparingVision develops genetic innovative therapies in ophthalmology for the treatment of blinding inherited retinal diseases.

Jeito is co-leading this round with the University of Pittsburgh Medical Center Enterprise (UMPCE), and with participation from Ysios Capital, 4Bio, Bpifrance and the RD Fund, the venture arm of Foundation Fighting Blindness (FFB).

Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough lead treatments, SPVN06 and SPVN20, for a very unique mutation-agnostic approach leading to new treatments in retinitis pigmentosa (RP) one of the leading inherited causes of blindness. Most notably, the funding will support SparingVision’s first-in-human studies, bringing lead assets to clinical validation. Proceeds will also accelerate the development of other innovative genomic medicines products of the pipeline.

SparingVision was Jeito’s first French investment following Jeito’s fund I launch in January 2020. In co-leading this Series B financing, Jeito Capital is demonstrating its commitment to invest significant capital in continuity, throughout the different development stages of a promising biotech company, to build market leaders with accelerated patients’ access globally, especially in Europe and the United States.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured